TFF Pharmaceuticals, announces positive preclinical data published in the Journal of Drug Delivery Science and Technology further validating the Company’s TFF technology as superior approach to formulate dry powders for pulmonary drug delivery. The study demonstrates the superiority of TFF inhalational dry powders over jet-milling and spray-drying technologies in a rat model, with enhanced uniform drug distribution in the lungs, lower airway-to-lung distribution ratio, and rapid disaggregation of particles of the TFF powder and subsequent particle movement of the resulting TFF nanoaggregates.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TFFP:
- TFF Pharmaceuticals announces new partnership with Emory University, BARDA
- TFF Pharmaceuticals announces preclinical data from influenza vaccine candidates
- TFFP Upcoming Earnings Report: What to Expect?
- TFF Pharmaceuticals Shares Update on Recent Developments
- TFF Pharmaceuticals provides continued positive outfomes from TFF TAC
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue